![]() Diabetes Obes Metab 20:121–128īergenstal R, Bailey TS, Rodbard D et al (2017) Comparison of insulin glargine 300 Units/mL and 100 units/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Home PD, Bergenstal RM, Bolli GB et al (2018) Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. J Natl Cancer Inst 22:719–748Ĭohen J (1988) Statistical power analysis for the behavioral sciences, Hillsdale Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. Higgins JP, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Workgroup on Hypoglycemia AeDA (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Higgins J, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Lau IT, Lee KF, So WY, Tan K, Yeung VTF (2017) Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes Obes Metab 17:254–260īrown MA, Davis CS, Fleming LW, Fleming JW (2016) The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus. Shiramoto M, Eto T, Irie S et al (2015) Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 17:1107–1114īecker RHA, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T (2015) New insulin glargine 300 Units.mL(-1) provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units.mL(-1). Diabetes Res Clin Pract 133:30–39ĭailey G, Lavernia F (2015) A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine. Graveling AJ, Frier BM (2017) The risks of nocturnal hypoglycaemia in insulin-treated diabetes. Diabetes Res Clin Pract 130:121–129įidler C, Elmelund Christensen T, Gillard S (2011) Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. Khunti K, Alsifri S, Aronson R et al (2017) Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ (2013) Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Miller KM, Foster NC, Beck RW et al (2015) Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry. The best current evidence indicates that Gla-300 reduces the incidence of nocturnal hypoglycemia with slight improvements in glycemic control compared with Gla-100 in both type 1 and type 2 diabetes adult patients. A small decrease in HbA 1c levels in favor of Gla-300 in the pooled sample was identified. Reductions in clinically significant nocturnal hypoglycemia events in type 1 diabetes patients were found. Compared with Gla-100, the use of Gla-300 reduced confirmed nocturnal hypoglycemia and clinically significant nocturnal hypoglycemia. Nine studies were included in the meta-analysis, including 3977 adult patients. Fixed- and random-effect models were used to estimate pooled RRs. The heterogeneity of results across studies was assessed using the I 2 statistic. The main outcome was the incidence rate ratio (RR) of nocturnal hypoglycemia events. We included randomized clinical trials comparing Gla-300 versus Gla-100 reporting the rate ratio or number of events of nocturnal hypoglycemia and HbA 1c levels percentage or mmol/mol −1. ![]() This study was registered with PROSPERO (CRD42017080134). We systematically searched in Medline, Embase, Web of Science, and Cochrane Central Register of Controlled Trials until July 4th, 2018. To assess the effectiveness of insulin glargine 300 ui/ml (Gla-300) compared with insulin glargine 100 ui/ml (Gla-100) on reducing nocturnal hypoglycemia and improving glycemic control in type 1 and type 2 diabetes patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |